Who are Intravenous thrombolysis agents's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fibrinolytic twice daily, low-dose tenecteplase intravenous thrombolysis, Fibrinolytic once daily, Low-dose intravenous tenecteplase, Fibrinolytic therapy, Intravenous Tenecteplase.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/intravenous-thrombolysis-agents.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Intravenous thrombolysis agents — Competitive Intelligence Brief

Intravenous thrombolysis agents (Intravenous thrombolysis agents) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thrombolytic agent / Fibrinolytic agent. Area: Cardiovascular.

phase 3 Thrombolytic agent / Fibrinolytic agent Plasminogen / Fibrin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Intravenous thrombolysis agents (Intravenous thrombolysis agents) — Second Affiliated Hospital, School of Medicine, Zhejiang University. Intravenous thrombolysis agents dissolve blood clots by converting plasminogen to plasmin, which breaks down fibrin and restores blood flow in occluded vessels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Intravenous thrombolysis agents TARGET	Intravenous thrombolysis agents	Second Affiliated Hospital, School of Medicine, Zhejiang University	phase 3	Thrombolytic agent / Fibrinolytic agent	Plasminogen / Fibrin
Fibrinolytic twice daily	Fibrinolytic twice daily	University of North Carolina, Chapel Hill	marketed	Fibrinolytic agent	Plasminogen / Fibrin
low-dose tenecteplase intravenous thrombolysis	low-dose tenecteplase intravenous thrombolysis	Southwest Hospital, China	marketed	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin
Fibrinolytic once daily	Fibrinolytic once daily	University of North Carolina, Chapel Hill	marketed	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
Low-dose intravenous tenecteplase	Low-dose intravenous tenecteplase	The George Institute	phase 3	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin
Fibrinolytic therapy	Fibrinolytic therapy	All India Institute of Medical Sciences	phase 3	Fibrinolytic agent / Thrombolytic	Plasminogen / Fibrin
Intravenous Tenecteplase	Intravenous Tenecteplase	NHS Greater Glasgow and Clyde	phase 3	Fibrinolytic agent / Tissue plasminogen activator (tPA)	Plasminogen / Fibrin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thrombolytic agent / Fibrinolytic agent class)

Second Affiliated Hospital, School of Medicine, Zhejiang University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Intravenous thrombolysis agents — Competitive Intelligence Brief. https://druglandscape.com/ci/intravenous-thrombolysis-agents. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab